Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of GFT505 80mg compared with placebo in
improving Oral Glucose Tolerance Test (OGTT), in patients with impaired glucose tolerance and
abdominal obesity, and to assess the tolerability and safety of once-a-day administrations of
oral doses of GFT505 during 35 days.